Stewart Parker, who has over 30 years of industry experience, has served as C3J Board Director and Chair of Compensation Committee since 2010, and as Chair of the Board since March 2016. Stewart is the Principal of Parker BioConsulting. Previously she was Chief Executive Officer of the Infectious Disease Research Institute (IDRI) in Seattle, from 2011 to 2014. Read More
Stewart was the Founding President and Chief Executive Officer of Targeted Genetics Corporation, a Seattle-based biotechnology company formed in 1992 to develop gene-based treatments for acquired and inherited disease. Prior to Targeted Genetics, Stewart held various positions at Immunex Corporation from 1981-1992, ending her tenure there as Vice President of Corporate Development, and President and Chief Executive Officer of its subsidiary Receptech Corporation. Stewart currently serves on the board of several companies including Nexgenia, Sangamo BioSciences, Impel NeuroPharma, and Oncogenex Pharmaceuticals. She is also a past Board member of the Seattle Branch of the Federal Reserve Bank of San Francisco. Stewart received her BA in Slavic Language and Literature from the University of Washington before completing an MBA in Finance and International Business from the University of Washington.
Mr. Patrick joined C3J as its President and CEO in November 2010. Prior to joining C3J, Todd served as President and Chief Operating Officer and joined the Board of Directors of ID Biomedical Corporation after the Company elected in 1998 to exit its core diagnostic business to focus on vaccines. Todd started ID Biomedical’s vaccine subsidiary in 1994. Read More
In September 2005, GlaxoSmithKline purchased ID Biomedical for approximately $1.5 billion plus the assumption of $200 million in debt. To date, the GSK/IDB merger is the second largest “pure play” enterprise value M&A transaction in the history of the vaccine industry. After retiring from ID Biomedical, Todd and a group of investors raised approximately $100 million for a portfolio of small medical companies. He was a director of each of these companies and also acted as a consultant for these and other biotech companies prior to ending his retirement to join C3J. Before he joined ID Biomedical, Todd was appointed the first ever Director of the Office of Intellectual Property Administration at UCLA, helping the organization start its IP program in 1989. Todd is the past Chairman of the Board of Trustees for the Seattle Biomedical Research Institute, a 400 person, non-profit global health organization focused on creating new drugs and vaccines to treat infectious diseases in the developing world. He is a past trustee of a variety of organizations in the Pacific Northwest, including the Washington Biotechnology and Biomedical Association (WBBA), and the WSU Research Foundation. He is on the Board of Directors of CRH Medical Corporation (NASDAQ listed) and privately held Vaxent Vaccines. Todd received his BA from the University of Washington and an MBA from Washington State University.
Ms. Czelada is President and Chief Executive Officer of Renaissance Health Service Corporation, where she has been employed since 1992. Read More
In this capacity, she oversees the enterprise’s financial systems, internal auditing and compliance, human resources, and information technology. Ms. Czelada was previously Executive Vice President, Chief Financial Officer and Chief Information Officer for Delta Dental of Michigan, Ohio and Indiana. Prior to joining Delta Dental she worked as a senior auditor for KPMG Peat Marwick. Ms. Czelada received a BA degree in accounting from Michigan State University in 1989 and became a Certified Public Accountant in 1991. She is a member of the American Institute of Certified Public Accountants and the Michigan Association of Certified Public Accountants.
Dr. Bastiani, who has over 40 years of industry experience, is currently a member of the Board of Directors of biotechnology companies Abaxis, DiscoveRx, and Pathwork Diagnostics. Read More
Formerly, Dr. Bastiani served as Chairman of the Board of Directors of ID Biomedical Corporation until its $1.5 billion acquisition by GlaxoSmithKline. Dr. Bastiani started his career at Palo Alto, CA-based Syva, where he held various positions over a 25-year career, ultimately becoming its President in 1991. Dr. Bastiani led Syva until its multi-billion dollar acquisition by Hoechst AG of Germany in 1995. After retiring from Syva, Dr. Bastiani served as President of Dendreon, a cancer therapeutic company.
Since 2006, Mr. Bisson has served as the Chief Executive Officer and President, and a member of the Board of Directors, of Water Pik, Inc. He was also Vice President of Operations at Waterpik Technologies from August 1999 to April 2006. He is the former Managing Director of Gilardoni S.P.A., an Italian provider of X-ray and ultrasonic products and related medical services.Read More
Additional leadership capabilities include senior-level manufacturing positions with Black & Decker and Philips Corp. He has 30 years experience in all aspects of operations as well as sales, marketing, product development, finance, mergers and aquisitions, accounting, and human resources.
Mr. Bisson holds a Bachelor’s Degree in Industrial Technology from Central Connecticut State University. He has completed the Executive Manufacturing Program at the University of Virginia Darden School of Business as well as Executive Financial Programs at the University of Chicago Booth School of Business.
Dr. Eichmiller is a nationally recognized authority in dental research and Vice President and Dental Director at Delta Dental of Wisconsin. He leads Delta Dental’s efforts to identify emerging technologies and trends in the dental industry, helps the company develop and expand its leadership in providing consumer-oriented oral health information, and represents the company within the dental community. Read More
Prior to joining Delta Dental, Dr. Eichmiller served as Director of the Paffenbarger Research Center, a dental research enterprise operated by the American Dental Association Health Foundation. The center, located in Gaithersburg, MD, engages in cooperative dental and medical materials research with government scientists and others, helping to develop standards, treatments, instruments and materials used by dentists nationwide. Dr. Eichmiller has published over 70 academic papers reflecting research on dental restorative materials and other dental-related topics. He is the recipient of several honors and awards, including the Hollenback Award for Dental Research from the Academy of Operative Dentistry, a Presidential Citation from the American Dental Association, and Clinician of The Year Award from the American Academy of Gold Foil Operators. Dr. Eichmiller received his BS and DDS degrees from the University of Minnesota, School of Dentistry.
Mr. Semmelmayer is a 32-year veteran of the dental industry. Prior to his 5 years as Chief Executive Officer of DenMat, he was the Chief Executive Officer of Discus Dental, a market-leading manufacturer and distributor of oral hygiene, small equipment, and tooth-whitening products operating in more than 100 countries. Steve was the Discus CEO from November 2008 until January 2011, when Discus merged with Koninklijke Philips Electronics. Read More
From 2006 to October 2008, he served as CEO and Chairman of the Board of LED Medical Diagnostics, a company dedicated to the early detection of oral cancer. From 1979 to 2006, Steve served in various capacities with Sybron Dental Specialties, a Danaher company, and global manufacturer of professional medical and dental products, including President, Professional Dental, from 2000 to 2006, President, Kerr Corp., from 1996 to 2000 and General Manager, Kerr Corp., from 1993 to 1996. Steve holds a Bachelor of Science from San Diego State University and an M.B.A. from Pepperdine University.
Dr. Wenyuan Shi serves as Chief Executive Officer and Chief Scientific Officer of the Forsyth Insitute, an independent not-for-profit research organization, located in Cambridge, MA. Forsyth is the only independent research institute in America specializing in oral health and its impact on overall wellness. Previously, Dr. Shi was Chairman and Professor of Oral Biology at the UCLA School of Dentistry and a Professor of Microbiology at the UCLA School of Medicine. Read More
Dr. Shi has been using multidisciplinary approaches to develop the next generation of diagnostic and therapeutic tools against oral microbial infections, including peptide-based targeted antimicrobial therapeutics and instant chairside detection of oral pathogens. These translational research efforts have resulted in novel technologies that are licensed and developed by major pharmaceutical, dental and biotech companies, including C3J Therapeutics, Inc. Dr. Shi obtained his BS degree from Fudan University in Shanghai in 1984, acquired his Doctoral degree from the University of Wisconsin-Madison in 1991, and fulfilled his postdoctoral training at the University of California Berkeley from 1992-1995. He is the co-author of over 200 scientific articles and is credited as co-inventor of 45 patents.